Despite additional cost savings in 2026, Pfizer also forecasts that its adjusted earnings per share (EPS) will likely decline ...

Pfizer is a Buy at low valuation but faces a 2030 patent cliff, COVID sales declines, and LOE risks. Click here to read an ...

Pfizer Inc. (PFE), headquartered in New York, discovers, develops, manufactures, markets, distributes, and sells ...

Pfizer (PFE) stock has attracted fresh attention after recent trading left its one-month return at a 3.3% decline and its ...

In the second quarter, Pfizer reported adjusted diluted earnings per share of $0.78 on revenue of nearly $14.7 billion. Both numbers came in well above expectations, with diluted EPS $0.20 higher than ...

Pfizer's 2026 revenue midpoint of $61B and EPS midpoint of $2.90 decline YoY, reflecting persisting headwinds. Read more on ...

Pfizer shares have emerged as a compelling contrarian investment opportunity as the pharmaceutical giant trades at historically attractive valuations following an extended period of market skepticism.

After reporting record revenue a few years ago, Pfizer has faced tougher times in recent quarters. Challenges include a decline in demand for coronavirus products and patent expirations on the horizon ...

Pfizer last month completed an acquisition of biotech firm Metsera, deepening its portfolio of products in the fast-growing market for weight loss drugs - Copyright ...

Shares of COVID-19 vaccine makers Pfizer Inc (NYSE:PFE), BioNTech SE ADR (NASDAQ:BNTX) and Moderna Inc (NASDAQ:MRNA) are trading lower Friday following a Washington Post report that Trump ...